StockData

NewAmsterdam Pharma vs uniQure

NAMS and QURE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NAMS and QURE compare

uniQure grew revenue faster over the last twelve months (30.2% versus −88.9% for NewAmsterdam Pharma).

uniQure keeps more of each dollar of sales as profit, with a net margin of −1351% compared with −3644% at NewAmsterdam Pharma.

NewAmsterdam Pharma scores higher on the StockData Score (6 against 4 for uniQure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNAMSQURE
Size and price
Market cap–$1.4B
Share price$19.39$20.78
Change, 1 year−49.4%−30.5%
Change, 5 years98.1%−27.9%
Beta (5Y)1.573.14
Employees100221
StockData Score
Total score6 (better)4
Valuation score00
Growth score02 (better)
Performance score1 (better)0
Health score5 (better)2
Dividend score00
Valuation
P/S–77.2×
P/B–4.4×
FCF yield–−11.2%
Fair value–$6.42
Margin of safety–−224%
Growth
Revenue growth (TTM)−88.9%30.2% (better)
Revenue growth, 5Y average–−15.6%
Profitability
Gross margin–92.5%
Operating margin−3432%−1072% (better)
Net margin−3644%−1351% (better)
FCF margin−2018%−865% (better)
Return on equity−36.8% (better)−158%
Return on invested capital−1046%–
Financial health
Debt / equity0.000.15 (better)
Interest coverage–−3.4×
Current ratio9.0310.01 (better)
Altman Z-score–−0.51
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield–0.00%
Ownership
Held by institutions–96.0%
Held by insiders22.0%2.1%
Insider net buying, 12 months−$63.0M−$20.2M (better)
Short interest, % of float–12.5%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.